Context: Previous case reports have documented the effectiveness of L-type calcium channel blockers (such as nifedipine and verapamil) for treating different forms of hyperinsulinemic hypoglycemia (HH).
H yperinsulinemic hypoglycemia (HH) is the most common cause of severe and persistent hypoglycemia during infancy (1) . Its incidence varies from 1:50,000 in western countries to 1:2500 in regions with high consanguinity (2) . It usually presents in the neonatal period and its prompt recognition and adequate management are paramount to avoid neurologic complications from hypoglycemic injury.
So far, mutations in 9 different genes involved in b-cell insulin release have been reported to cause congenital HH. These genes are ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, UCP2, HN4A, and HNF1A (1). ABCC8 and KCNJ11 genes encode for the 2 subunits that form the adenosine triphosphate (ATP)-sensitive potassium channels (K ATP channels) in the membrane of pancreatic b-cells. In 50% of patients with persistent congenital HH, a mutation in ABCC8 or KCNJ11 will be identified (1) . Mutations in the genes ABCC8 (encodes for SUR1 subunit) and KCNJ11 (encodes for Kir6.2 subunit) cause the most severe forms of HH that are usually medically unresponsive. The closure of these K ATP channels initiates the depolarization of the b-cell membrane and opening of calcium channels, which results in influx of calcium in the cell, leading to augmented intracellular calcium that triggers insulin release (3, 4) . Figure 1 shows a schematic cartoon of the b-cell with the genes and channels involved in insulin secretion. These voltage-operated calcium channels belong to different types depending on their pharmacological properties: those expressed in human b-cells are L (CaV1.1 to 1.4; dihydropyridine sensitive), P/Q (CaV2.1, v-agatoxin sensitive), and T (CaV3.1 to 3.3, low-voltage activated) (5, 6) . When the L-type channel is activated, there is an increase insulin release after a nonglucose depolarizing stimulus (7) , whereas the ablation of this channel in mice leads to impaired insulin secretion and glucose intolerance (8) .
In patients with HH, the first-line medical therapy includes the administration of diazoxide. However, the vast majority of patients with persistent HH due to mutations in the K ATP channels genes (ABCC8/KCNJ11) do not respond to diazoxide therapy. Other medical therapies which have been used in patients with HH include short and long-acting octreotide preparations, mTOR inhibitors such as sirolimus, and nifedipine.
Nifedipine is an agent that blocks the L-type calcium channel. Nimodipine, verapamil, and diltiazem are also L-type calcium blockers that have been shown to in vitro inhibit the secretion of insulin in rodent islets (9) (10) (11) and likewise isradipine in human islets (5) . Nimodipine and verapamil have been shown to be inhibitory in mouse beta cells that are continuously stimulated by their lack of K ATP channels as are beta cells from the infants with Sur1 or Kir6.2 inactivating mutations (9) . In vitro electrophysiological studies on isolated islets from a premature baby with persistent HH demonstrated that verapamil reversibly blocks the calcium dependent action potentials (12) .
There are at least 11 case reports in the medical literature where nifedipine therapy has been used for the treatment of HH (see Table 1 ), as this condition is one of the indications for this treatment. These case reports show the effect of nifedipine either on its own (13), combined with dietary management (14) or with other medications (15, 16) . In some reports, nifedipine was introduced with the aim to avoid the side effects of other medications (i.e., diazoxide, octreotide, etc.) or with a concomitant antihypertensive purpose (14) . However, despite these case reports there have not been any previous thorough clinical studies assessing the effectiveness of nifedipine therapy for patients with persistent HH due to mutation in the K ATP channel genes.
The purpose of this prospective study of a series of 11 patients with persistent HH due to mutations in the ABCC8 gene was to assess the glycemic response to dose escalation of nifedipine therapy.
Subjects and Methods
This study was ethically approved by the Ethics Committee of Great Ormond Street Hospital National Health Service Trust and the Institute of Child Health, University College London. Eleven consecutive children with biochemically confirmed HH due to mutations in the ABCC8 gene and diazoxideunresponsiveness were recruited into this study. All subjects were inpatients while nifedipine was tried. The starting dose of nifedipine was 0.25 mg/kg/d divided in 3 daily doses, and the escalation protocol involved increasing the dose by 0.5mg/kg/d every 24 hours, if no positive glycemic response identified, up to a maximum of 2.5 mg/kg/d. The dose of nifedipine was withheld in case of hypotension, which, for those under 1 year of age, was defined by the Pediatric Advanced Life Support course guidelines (17) and for those over 1 year of age, if the systolic blood pressure was under the 5th percentile for gender and age (18) . Two-hourly blood glucose monitoring was performed throughout the days when nifedipine was tried, and this was determined on capillary samples obtained by heel-stick and using a glucose meter. A positive effect would be defined by improvement in glycemic control, avoidance of hypoglycemic episodes, and reduction of intravenous glucose infusion or doses of concomitantly administered medications.
Genetic testing had been previously performed at the genetics laboratory in Exeter, United Kingdom. An 18-Fluor-DOPA-PET scan was performed in cases with genetic results suggestive of a focal lesion and those with unknown genetics and diazoxide unresponsive, and this was carried out in the nuclear medicine department at University College London Hospital. A literature review was performed by PubMed search using the Medical Subject Headings terms calcium channel blockers, nifedipine, hypoglycemia, and hyperinsulinism.
Results
A PubMed review of the cases published in the literature regarding nifedipine use in children with HH was performed and the results of these studies are summarized in Table 1 . Eleven children with HH due to ABCC8 gene mutations were recruited. Their gender, family history, genetics, form of HH, birth characteristics and age at presentation of HH are summarized in Table 2 . None of the patients had any syndromic features. The median gestational age was 39 weeks (range 35 + 3 to 42 weeks) and the median birth weight was 4.035 kg (3.13 to 4.74 kg) or +1.7 standard deviation score (SDS; range: 1.07 to 3.05). Table 3 shows the results of the nifedipine study and the final outcome for each patient. The age when nifedipine was tested was at a median of 0.42 years (0.14 to 3.77), and the median time it was tried for was 6 days (3-20, 26, 29, 30) . Auxology was within normal limits in most patients except for case number 3 with a weight .2 SDS and patient number 8 with a length .2 SDS. All children received a maximum dose of 2.5 mg/kg/d as per the protocol.
Discussion
In vitro studies in rodent (9-11) and human (12) b-cells demonstrate that calcium channel blockers can reduce insulin release from the b-cell. In vivo studies in rats and dogs with diltiazem show no effect on glucose-induced insulin secretion (29) , whereas intravenous verapamil administered to healthy humans inhibits insulin secretion following oral glucose or oral glibenclamide or intramuscular glucagon injection (30) . Subjects with insulinoma who received diltiazem or verapamil had less occurrence of hypoglycemia (30) . If proven useful for the management of HH, calcium channel blockers would be a helpful alternative medical option to avoid a near total/ partial pancreatectomy and the side effects of the other medical therapies.
Our study assessed the effectiveness of nifedipine therapy (up to a maximum dose of 2.5 mg/kg/d) in a relatively large cohort of patients with mutations in the ABCC8 gene. There was no positive glycemic effect in any patient and we were not able to wean the intravenous glucose infusion or reduce any of the concomitant medications, as reported in other cases (19) . In fact we observed no improvement in the blood glucose level at all in any patient despite giving nifedipine up to a maximum dose 2.5 mg/kg/d. Other centers have reported this same experience (2), although ours is the first study to formally assess the response to this dose in a cohort of cases following a systematic approach. Unfortunately, the 2-hourly glucose readings while on nifedipine were not included in our study database given the difficulty in combining all the patient's measurements together over the course of several days; hence, this is a limitation to our study. Previous case reports on the use of nifedipine in patients with HH lack details on the characteristics of the patients in whom this drug was administered, namely genetic cause of HH, assessment of response (fasting tolerance on nifedipine prior discharge is not available in the majority of reports), side effects, and follow-up, as presented in Table 1 . Reports in the literature include transient (26) as well as persistent HH (19, 20) , mild (19) , and severe (13) cases. Some reports have shown that patients have responded to small doses of nifedipine, whereas in the current study, the subjects received up to the maximum dose (2.5 mg/kg/d) without observing glycemic improvement at all.
Several reports describe glycemic control in monotherapy (20) , although in some cases, only after 2 pancreatectomies (13) . Many reports state that glycemic control was only achieved when another agent was added such as octreotide (15) , lanreotide (22) , the combination of diazoxide plus octreotide (16) , or in addition to frequent feeds (14) or cornstarch (21) . There is likely to be a publication bias as studies where nifedipine has not been effective may have not been published. Only 1 case, to the best of our knowledge, has been published of an infant who, after 2 pancreatectomies, did not respond to nifedipine but was controlled on a subcutaneous glucagon infusion pump (27) .
Calcium channel antagonists have also been used in adults with what has been labeled as adult-onset nesidioblastosis or histologically confirmed hyperinsulinism. Abbreviations: BW, birth weight; GH, growth hormone; GM, grandmother; GOR, gastro-oesophageal reflux; HC, hydrocortisone; HI, hyperinsulinism; Inj, injection; IV, intravenous; LVH, left ventricular hypertrophy; PDA, patent ductus arteriosum; PET, positron emission tomography; Pt, patient. a After the first 90% pancreatectomy, nifedipine (0.5 mg/kg/d) was unsuccessfully tried with somatostatin infusion (0.53 g/kg/h), oral diazoxide (20 mg/kg/d), hydrochlorothiazide (7 mg/kg/d), and glucose infusion at16 mg/kg/min. Nifedipine was retried after the second pancreatectomy and was successful.
ruled out and calcium-stimulated insulin release arteriography study revealed nonlocalized insulin secretion. She was treated with nifedipine 30 mg sustained release once daily and remained free of symptomatic hypoglycemia for 20 months with no hypoglycemic readings in her home monitor (33) . The only side effects were mild orthostatic hypotension and constipation on a 3-times-aday regimen. Our patients were tried on this medication at an early age, so it could be hypothesized that, as evidenced from press.endocrine.org/journal/jcemadult reports, nifedipine might be beneficial in adulthood once the natural course of the disease is milder. Given that there are many organs whose function relies on cellular calcium influx and the state of membrane depolarization, caution should be exerted regarding longterm use of calcium channel blockade. Verapamil, which has been used in in vitro studies (9, 12) , has more effect than nifedipine on myocardial function; hence, patients receiving it should be selected carefully. Hypotension as a side effect was reported in an HH case (15) , and this was also observed in our study. Possible side effects of calcium channel blockers include flushing, dizziness, headaches, nausea, and constipation, among others (34) .
Other calcium blockers used for hypertension have shown effect on blood glucose concentrations. A patient with hypertension and congenital hyperinsulinism due to a KCNJ11 mutation satisfactorily increased the baseline mean blood glucose level and avoided hypoglycemia episodes with the combination of octreotide (a somatostatin analog) and amlodipine (a L-type calcium-channel blocker) (14) . A synergistic effect of octreotide could be hypothesized given that octreotide inhibits the entrance of calcium into the b-cell through L-type voltage operated calcium channels, hence avoiding the release of insulin (35) . Also, in insulinoma b-cells, octreotide activates K ATP channel leading to membrane hyperpolarization and decrease of insulin secretion (36) . In this study by de Weille et al. (36) , the authors state that the addition of amlodipine allowed the spacing of the octreotide injections to increase from every 6 hours to every 8 hours, improving the quality of life (14) . The 11 subjects included in this study represent different mutations in the ABCC8 gene, yet none of them demonstrated a positive glycemic response. Mechanistic insights in this area are few because animal models of ABCC8 mutations do not seem to recapitulate the phenotype demonstrated here (37) . It is possible that the response to calcium blockers relies on the underlying genetic defect and that K ATP channel genes might alter the function of the L-type calcium channel, this rendering it ineffective to therapy with nifedipine. It may be worth exploring the potential use of P/Q-type calcium channel inhibitors, as Braun et al. (5) demonstrated that this type of channel plays a role in insulin exocytosis in human islets and glucose-stimulated insulin release was greatly suppressed by its specific blocker (v-agatoxin number 4 channel 4).
In conclusion, nifedipine therapy is ineffective in patients with mutations in the ABCC8 gene. The reason for the discrepancy in response to calcium channel blockers between in vitro experiments and this in vivo study is uncertain.
